Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: J Subst Use Addict Treat. 2023 Dec 14;158:209261. doi: 10.1016/j.josat.2023.209261

Table A.1.

Participant Characteristics and Bup Treatment Continuation at Post-hospital Follow-up, 30 days and 90 days* Among Patients with OUD, N = 22

Patient-related characteristics
Bupe rx at follow-up n = 10 No bupe rx at followup n = 12 p-value Bupe rx 30 days n = 8 No bupe rx 30 days n = 14 p-value Bupe rx 90 days n = 8 No bupe rx 90 days n = 14 p-value
Age: median (IQR) 56 (46, 59) 44 (40, 61) NS 57 (66, 47) 46 (40, 60) NS 57 (47, 66) 46 (40, 60) NS
Gender (man) 5 (50.0) 7 (58.3) NS 5 (62.5) 7 (50.0) NS 5 (62.5) 7 (50.0) NS
Race (white) 7 (70.0) 11 (91.7) NS 7 (87.5) 11 (78.6) NS 7 (87.5) 11 (78.6) NS
Ethnicity Latino/a/x (yes) 6 (60.0) 4 (33.3) NS 4 (50.0) 8(57.1) NS 4 (50.0) 8(57.1) NS
Insurance Type Medicaid 6 (60.0) 7 (58.3) NS 4 (50.0) 9 (64.3) NS 4 (50.0) 9 (64.3) NS
Stably Housed (yes) 7 (70.0) 8 (66.7) NS 7 (87.5) 8(57.1) NS 7 (87.5) 8(57.1) NS
Mental Health Diagnosis (yes) 7 (70.0) 7 (58.3) NS 6 (75.0) 8(57.1) NS 6 (75.0) 8(57.1) NS
Prior bupe rx (yes) 7 (70.0) 5 (41.7) NS 5 (62.5) 7 (50.0) NS 5 (62.5) 7 (50.0) NS
History of Precipitated Withdrawal (yes) 2 (20.0) 3 (25.0) NS 2 (25.0) 3 (21.4) NS 2 (25.0) 3 (21.4) NS
Primary Opioid Used
 Rx opioids 3 (30.0) 4 (33.3) NS 3 (37.5) 4 (28.6) NS 3 (37.5) 4 (28.6) NS
 Heroin and/or fentanyl 6 (60.0) 7 (58.3) NS 4 (50.0) 9 (64.3) NS 4 (50.0) 9 (64.3) NS
 Methadone 1 (10.0) 1 (8.3) NS 1 (12.5) 1 (7.1) NS 1 (12.5) 1 (7.1) NS
Enrolled in methadone treatment (yes) 3 (25.0) 3 (30.0) NS 2 (22.2) 4 (30.8) NS 2 (25.0) 4 (28.6) NS
 Preadmission methadone treatment dose (mg): median (IQR) 30 (30, 70) 60 (60, 155) NS 30 (30, 30) 65 (60, 113) NS 30 (30, 30) 65 (60, 113) NS
Lifetime overdose history (yes) 3 (30.0) 6 (50.0) NS 1 (12.5) 8(57.1) NS 1 (12.5) 8(57.1) NS
Methadone During Admission (yes) 7 (70.0) 10 (83.3) NS 5 (62.5) 12 (85.7) NS 5 (62.5) 12 (85.7) NS
 Continued from pre-admission 3 (25) 3 (30) NS 2 (22.2) 4 (30.8) NS 2 (25.0) 4 (28.6) NS
 Started during admission 6 (50.0) 5 (50.0) NS 4 (44.4) 7 (53.9) NS 3 (37.5) 8(57.1) NS
Treatment-related characteristics
Days admitted to hospital: median (IQR) 12.5 (5.5,17.5) 11 (5, 28.5) NS 12.5 (5, 17) 11 (6, 18) NS 11 (5, 17) 13 (6, 21) NS
Reason for low-dose initiation
 Transition off methadone 6 (60.0) 8 (66.7) NS 4 (50.0) 10 (71.4) NS 4 (50.0) 10 (71.4) NS
 Transition off opioid analgesics 2 (20.0) 2 (16.7) NS 2 (25.0) 2 (14.3) NS 2 (25.0) 2 (14.3) NS
 History of precipitated withdrawal 2 (20.0) 3 (25.0) NS 2 (25.0) 3 (21.4) NS 2 (25.0) 2 (14.3) NS
Low-dose initiation days: median (IQR) 4.5 (4, 6) 5 (2.5, 7.5) NS 4.5 (3, 6) 5 (3, 7) NS 5 (3, 6) 5 (3, 7) NS
Highest COWS: median (IQR) 1 (0, 8) 1.5 (0, 9) NS 1 (1, 8) 1.5 (0, 6) NS 2 (1, 8) 2 (0, 6) NS
Precipitated withdrawal (yes) 2 (20.0) 2 (16.7) NS 2 (25.0) 2 (14.3) NS 2 (25.0) 2 (14.3) NS
Left hospital prior to completion (yes) 4 (40.0) 4 (33.3) NS 4 (50) 4 (28.6) NS 4 (50.0) 4 (28.6) NS
Initiation completed as inpatient (yes) 6 (60.0) 3 (100) NS 4 (50.0) 0 (0) NS 4 (50.0) 5 (100.0) NS
Opioids taken in 24 hrs prior
 Methadone 5 (50.0) 9 (75.0) NS 3 (37.5) 11 (78.6) NS 3 (37.5) 11 (78.6) NS
 Other opioids 2 (20.0) 2 (16.7) NS 2 (25.0) 2 (14.3) NS 2 (25.0) 2 (14.3) NS
 None 3 (30.0) 1 (8.3) NS 3 (37.5) 1 (7.1) NS 3 (37.5) 1 (7.1) NS
Overlapping opioid
 Methadone 5 (50.0) 9 (75.0) NS 3 (21.4) 11 (78.6) NS 3 (37.5) 11 (78.6) NS
 Other opioids 3 (30.0) 3 (25.0) NS 3 (37.5) 3 (21.4) NS 3 (37.5) 3 (21.4) NS
 None 2 (20.0) 0 (0) NS 2 (25.0) 0 (0) NS 2 (25.0) 0 (0) NS
Supplemental opioid MME: median (IQR) 111 (8, 800) 1907 (872, 3548) 0.01 96 (3.8, 720) 1640 (363, 2496) 0.02 96 (4, 720) 1640 (363, 2496) 0.02

Bup, buprenorphine; IQR, interquartile range; SUD, substance use disorder; OUD, opioid use disorder; rx, prescription; COWS, Clinical Opiate Withdrawal Score; Bolded = statistically significant